Digimed Updates
  • Home
  • SAHI Updates
  • News
  • Conference
    • ADA 2025
    • HFAI 2025
    • ATTD 2024
    • ADA 2024
    • ENDO 2022
    • ESH 2022
    • ADA 2022
    • AACE 2022
    • EASD-2021
    • HFSA-2021
    • ESC-2021
    • ADA 2021
    • ACC-2021
    • ESH-ISH-2021
    • ADA 2020
    • RSSDI 2020
    • ACC-2020
    • IDF-2019
    • EASD-2019
    • ESH-2019
    • ADA-2019
    • RSSDI-2018
    • EASD-2018
  • Specialties
    • Cardiology
    • Endocrinology
    • Conference Update
    • Other Specialties Conference
  • Subscribe
  • Contact
Select Page
Cardiac pacing in severe recurrent reflex syncope and tilt-induced asystole

Cardiac pacing in severe recurrent reflex syncope and tilt-induced asystole

The study suggest the utility of tilt testing as a method for selecting pacemaker candidates.

Premature Menopause, Clonal Hematopoiesis, and Coronary Artery Disease in Postmenopausal Women

Premature Menopause, Clonal Hematopoiesis, and Coronary Artery Disease in Postmenopausal Women

Natural premature menopause may represent a risk signal for latent genomic instability and predilection to develop CHIP and CHIP-associated cardiovascular disease.

Effects of n-3 Fatty Acid Supplements in Elderly Patients after Myocardial Infarction: A Randomized Controlled Trial

Effects of n-3 Fatty Acid Supplements in Elderly Patients after Myocardial Infarction: A Randomized Controlled Trial

First study to show that a genetic risk score remains an independent predictor of ischemic stroke in subjects who are older and have established cardiometabolic disease.

A Plasma Lipid Signature Predicts Incident Coronary Artery Disease

A Plasma Lipid Signature Predicts Incident Coronary Artery Disease

First study to show that lipidomic measurements can be used to achieve significant improvements in risk prediction of CAD in a large cohort with long-term follow-up

Novel Antisense Therapy Targeting microRNA-132 in Patients with Heart Failure: Results of a First-in-human Phase 1b Randomized, Double-blind, Placebo-controlled Study

Novel Antisense Therapy Targeting microRNA-132 in Patients with Heart Failure: Results of a First-in-human Phase 1b Randomized, Double-blind, Placebo-controlled Study

This study is the first clinical trial of an antisense drug CDR132L in HF patients.

« Older Entries
Next Entries »
« Previous 1 … 70 71 72 73 74 … 87 Next »
  • Home
  • News
  • Conference
  • Subscribe
  • Contact
The material on this site is for informational purposes only, and is not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider.
© 2021 Digimed India. All rights reserved.
  • Home
  • News
  • Conference
  • Subscribe
  • Contact
  • Facebook
  • Twitter
  • Google
  • Instagram
  • RSS

Designed by Elegant Themes | Powered by WordPress